25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

KAPA (Kairos Pharma, Ltd.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Kairos Pharma, Ltd. together

I guess you are interested in Kairos Pharma, Ltd.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Kairos Pharma, Ltd.’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Kairos Pharma, Ltd.’s Price Targets

I'm going to help you getting a better view of Kairos Pharma, Ltd.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Kairos Pharma, Ltd.

I send you an email if I find something interesting about Kairos Pharma, Ltd..

1. Quick Overview

1.1. Quick analysis of Kairos Pharma, Ltd. (30 sec.)










1.2. What can you expect buying and holding a share of Kairos Pharma, Ltd.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.35
Expected worth in 1 year
$0.75
How sure are you?
54.5%

+ What do you gain per year?

Total Gains per Share
$0.40
Return On Investment
23.9%

For what price can you sell your share?

Current Price per Share
$1.68
Expected price per share
$0.825 - $3.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Kairos Pharma, Ltd. (5 min.)




Live pricePrice per Share (EOD)
$1.68

2.2. Growth of Kairos Pharma, Ltd. (5 min.)




Is Kairos Pharma, Ltd. growing?

Current yearPrevious yearGrowGrow %
How rich?$5.9m-$1m$6.3m120.5%

How much money is Kairos Pharma, Ltd. making?

Current yearPrevious yearGrowGrow %
Making money-$1.1m-$501.5k-$676.2k-57.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Kairos Pharma, Ltd. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Kairos Pharma, Ltd.?

Welcome investor! Kairos Pharma, Ltd.'s management wants to use your money to grow the business. In return you get a share of Kairos Pharma, Ltd..

First you should know what it really means to hold a share of Kairos Pharma, Ltd.. And how you can make/lose money.

Speculation

The Price per Share of Kairos Pharma, Ltd. is $1.68. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kairos Pharma, Ltd..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kairos Pharma, Ltd., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.35. Based on the TTM, the Book Value Change Per Share is $0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kairos Pharma, Ltd..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.08-4.9%-0.07-4.1%-0.03-1.8%-0.04-2.3%-0.04-2.3%-0.04-2.3%
Usd Book Value Change Per Share-0.07-4.5%0.106.0%0.010.6%0.031.9%0.031.9%0.031.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-4.5%0.106.0%0.010.6%0.031.9%0.031.9%0.031.9%
Usd Price Per Share0.71-1.18-0.00-0.43-0.43-0.43-
Price to Earnings Ratio-2.15--4.53-0.00--1.65--1.65--1.65-
Price-to-Total Gains Ratio-9.47-5.31-5.31-5.31-5.31-
Price to Book Ratio2.04-4.39-0.00-1.60-1.60-1.60-
Price-to-Total Gains Ratio-9.47-5.31-5.31-5.31-5.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.68
Number of shares595
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.100.03
Usd Total Gains Per Share0.100.03
Gains per Quarter (595 shares)59.6418.85
Gains per Year (595 shares)238.5575.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1023922907565
204774680151140
307167070226215
409549460302290
50119311850377365
60143114240452440
70167016630528515
80190819020603590
90214721410678665
100238523800754740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%
Book Value Change Per Share3.01.00.075.0%6.05.00.054.5%6.05.00.054.5%6.05.00.054.5%6.05.00.054.5%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%
Total Gains per Share3.01.00.075.0%6.05.00.054.5%6.05.00.054.5%6.05.00.054.5%6.05.00.054.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Kairos Pharma, Ltd. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0750.100-175%0.010-847%0.032-336%0.032-336%0.032-336%
Book Value Per Share--0.3480.313+11%-0.064+119%0.069+408%0.069+408%0.069+408%
Current Ratio--7.1585.428+32%0.044+16238%2.046+250%2.046+250%2.046+250%
Debt To Asset Ratio--0.1010.177-43%2.112-95%1.473-93%1.473-93%1.473-93%
Debt To Equity Ratio--0.1130.234-52%-+100%0.085+33%0.085+33%0.085+33%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--14562029.05321440327.713-32%--21440327.713-32%21440327.713-32%21440327.713-32%
Eps---0.083-0.069-16%-0.030-64%-0.039-53%-0.039-53%-0.039-53%
Ev To Ebitda Ratio---2.500-4.708+88%---4.708+88%-4.708+88%-4.708+88%
Free Cash Flow Per Share---0.047-0.079+69%0.000-12708%-0.029-37%-0.029-37%-0.029-37%
Free Cash Flow To Equity Per Share---0.0340.045-175%-0.003-91%0.014-348%0.014-348%0.014-348%
Gross Profit Margin--1.0001.033-3%1.0000%1.012-1%1.012-1%1.012-1%
Market Cap28306824.000+57%12204029.05320009827.713-39%-+100%7276300.987+68%7276300.987+68%7276300.987+68%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio4.822+58%2.0354.387-54%-+100%1.595+28%1.595+28%1.595+28%
Pe Ratio-5.084-137%-2.146-4.530+111%--100%-1.647-23%-1.647-23%-1.647-23%
Price Per Share1.680+58%0.7091.184-40%-+100%0.430+65%0.430+65%0.430+65%
Price To Free Cash Flow Ratio-8.981-137%-3.790-4.034+6%--100%-1.467-61%-1.467-61%-1.467-61%
Price To Total Gains Ratio-22.435-137%-9.4685.309-278%--5.309-278%5.309-278%5.309-278%
Quick Ratio--4.4882.953+52%0.035+12637%1.140+294%1.140+294%1.140+294%
Return On Assets---0.213-0.188-12%-0.516+142%-0.308+45%-0.308+45%-0.308+45%
Return On Equity---0.237-0.233-2%--100%-0.085-64%-0.085-64%-0.085-64%
Total Gains Per Share---0.0750.100-175%0.010-847%0.032-336%0.032-336%0.032-336%
Usd Book Value--5997000.0005309250.000+13%-1086250.000+118%1166090.909+414%1166090.909+414%1166090.909+414%
Usd Book Value Change Per Share---0.0750.100-175%0.010-847%0.032-336%0.032-336%0.032-336%
Usd Book Value Per Share--0.3480.313+11%-0.064+119%0.069+408%0.069+408%0.069+408%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--14562029.05321440327.713-32%--21440327.713-32%21440327.713-32%21440327.713-32%
Usd Eps---0.083-0.069-16%-0.030-64%-0.039-53%-0.039-53%-0.039-53%
Usd Free Cash Flow---805000.000-1335500.000+66%6250.000-12980%-496545.455-38%-496545.455-38%-496545.455-38%
Usd Free Cash Flow Per Share---0.047-0.079+69%0.000-12708%-0.029-37%-0.029-37%-0.029-37%
Usd Free Cash Flow To Equity Per Share---0.0340.045-175%-0.003-91%0.014-348%0.014-348%0.014-348%
Usd Market Cap28306824.000+57%12204029.05320009827.713-39%-+100%7276300.987+68%7276300.987+68%7276300.987+68%
Usd Price Per Share1.680+58%0.7091.184-40%-+100%0.430+65%0.430+65%0.430+65%
Usd Profit---1422000.000-1177750.000-17%-501500.000-65%-663181.818-53%-663181.818-53%-663181.818-53%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---0.0750.100-175%0.010-847%0.032-336%0.032-336%0.032-336%
 EOD+5 -3MRQTTM+13 -20YOY+12 -163Y+13 -205Y+13 -2010Y+13 -20

3.3 Fundamental Score

Let's check the fundamental score of Kairos Pharma, Ltd. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.084
Price to Book Ratio (EOD)Between0-14.822
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.488
Current Ratio (MRQ)Greater than17.158
Debt to Asset Ratio (MRQ)Less than10.101
Debt to Equity Ratio (MRQ)Less than10.113
Return on Equity (MRQ)Greater than0.15-0.237
Return on Assets (MRQ)Greater than0.05-0.213
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Kairos Pharma, Ltd. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.620
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Kairos Pharma, Ltd.

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

Fundamental data was last updated by Penke on 2025-08-16 19:54:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Kairos Pharma, Ltd. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kairos Pharma, Ltd.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM--171.0%+171.0%
YOY--210.0%+210.0%
3Y--289.9%+289.9%
5Y--381.1%+381.1%
10Y--520.3%+520.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Kairos Pharma, Ltd. is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • -21.3% Return on Assets means thatΒ Kairos Pharma, Ltd. generatedΒ $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kairos Pharma, Ltd.:

  • The MRQ is -21.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -18.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.3%TTM-18.8%-2.5%
TTM-18.8%YOY-51.6%+32.9%
TTM-18.8%5Y-30.8%+12.1%
5Y-30.8%10Y-30.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.3%-11.9%-9.4%
TTM-18.8%-11.9%-6.9%
YOY-51.6%-11.2%-40.4%
3Y-30.8%-12.0%-18.8%
5Y-30.8%-11.7%-19.1%
10Y-30.8%-13.8%-17.0%
4.3.1.3. Return on Equity

Shows how efficient Kairos Pharma, Ltd. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • -23.7% Return on Equity means Kairos Pharma, Ltd. generated $-0.24Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kairos Pharma, Ltd.:

  • The MRQ is -23.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.7%TTM-23.3%-0.4%
TTM-23.3%YOY--23.3%
TTM-23.3%5Y-8.5%-14.9%
5Y-8.5%10Y-8.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.7%-14.2%-9.5%
TTM-23.3%-15.2%-8.1%
YOY--15.3%+15.3%
3Y-8.5%-16.9%+8.4%
5Y-8.5%-17.5%+9.0%
10Y-8.5%-19.6%+11.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Kairos Pharma, Ltd..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Kairos Pharma, Ltd. is operatingΒ .

  • Measures how much profit Kairos Pharma, Ltd. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kairos Pharma, Ltd.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM--280.2%+280.2%
YOY--268.7%+268.7%
3Y--281.5%+281.5%
5Y--350.8%+350.8%
10Y--530.7%+530.7%
4.3.2.2. Operating Ratio

Measures how efficient Kairos Pharma, Ltd. is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kairos Pharma, Ltd.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.952-1.952
TTM-2.974-2.974
YOY-3.047-3.047
3Y-3.835-3.835
5Y-4.924-4.924
10Y-6.864-6.864
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Kairos Pharma, Ltd..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Kairos Pharma, Ltd. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.16Β means the company has $7.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kairos Pharma, Ltd.:

  • The MRQ is 7.158. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.428. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.158TTM5.428+1.730
TTM5.428YOY0.044+5.384
TTM5.4285Y2.046+3.382
5Y2.04610Y2.0460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1583.480+3.678
TTM5.4283.790+1.638
YOY0.0444.104-4.060
3Y2.0464.609-2.563
5Y2.0465.764-3.718
10Y2.0466.154-4.108
4.4.3.2. Quick Ratio

Measures if Kairos Pharma, Ltd. is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • A Quick Ratio of 4.49Β means the company can pay off $4.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kairos Pharma, Ltd.:

  • The MRQ is 4.488. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.953. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.488TTM2.953+1.536
TTM2.953YOY0.035+2.917
TTM2.9535Y1.140+1.812
5Y1.14010Y1.1400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4882.938+1.550
TTM2.9533.291-0.338
YOY0.0353.928-3.893
3Y1.1404.393-3.253
5Y1.1405.837-4.697
10Y1.1406.549-5.409
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Kairos Pharma, Ltd..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Kairos Pharma, Ltd.Β assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Kairos Pharma, Ltd. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10Β means that Kairos Pharma, Ltd. assets areΒ financed with 10.1% credit (debt) and the remaining percentage (100% - 10.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Kairos Pharma, Ltd.:

  • The MRQ is 0.101. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.177. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.101TTM0.177-0.076
TTM0.177YOY2.112-1.934
TTM0.1775Y1.473-1.296
5Y1.47310Y1.4730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1010.339-0.238
TTM0.1770.359-0.182
YOY2.1120.334+1.778
3Y1.4730.341+1.132
5Y1.4730.349+1.124
10Y1.4730.379+1.094
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Kairos Pharma, Ltd. is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 11.3% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kairos Pharma, Ltd.:

  • The MRQ is 0.113. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.234. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.113TTM0.234-0.121
TTM0.234YOY-+0.234
TTM0.2345Y0.085+0.149
5Y0.08510Y0.0850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1130.391-0.278
TTM0.2340.436-0.202
YOY-0.436-0.436
3Y0.0850.461-0.376
5Y0.0850.461-0.376
10Y0.0850.514-0.429
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Kairos Pharma, Ltd. generates.

  • Above 15 is considered overpriced butΒ always compareΒ Kairos Pharma, Ltd. to theΒ Biotechnology industry mean.
  • A PE ratio of -2.15 means the investor is paying $-2.15Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kairos Pharma, Ltd.:

  • The EOD is -5.084. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.146. Based on the earnings, the company is expensive. -2
  • The TTM is -4.530. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.084MRQ-2.146-2.938
MRQ-2.146TTM-4.530+2.384
TTM-4.530YOY--4.530
TTM-4.5305Y-1.647-2.883
5Y-1.64710Y-1.6470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.084-2.539-2.545
MRQ-2.146-2.361+0.215
TTM-4.530-2.657-1.873
YOY--3.749+3.749
3Y-1.647-3.883+2.236
5Y-1.647-6.353+4.706
10Y-1.647-7.102+5.455
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kairos Pharma, Ltd.:

  • The EOD is -8.981. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.790. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.034. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.981MRQ-3.790-5.191
MRQ-3.790TTM-4.034+0.244
TTM-4.034YOY--4.034
TTM-4.0345Y-1.467-2.567
5Y-1.46710Y-1.4670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.981-3.411-5.570
MRQ-3.790-2.951-0.839
TTM-4.034-3.614-0.420
YOY--4.421+4.421
3Y-1.467-5.258+3.791
5Y-1.467-8.587+7.120
10Y-1.467-9.639+8.172
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Kairos Pharma, Ltd. is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.04 means the investor is paying $2.04Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kairos Pharma, Ltd.:

  • The EOD is 4.822. Based on the equity, the company is fair priced.
  • The MRQ is 2.035. Based on the equity, the company is underpriced. +1
  • The TTM is 4.387. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.822MRQ2.035+2.787
MRQ2.035TTM4.387-2.352
TTM4.387YOY-+4.387
TTM4.3875Y1.595+2.792
5Y1.59510Y1.5950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.8222.206+2.616
MRQ2.0352.027+0.008
TTM4.3872.194+2.193
YOY-2.425-2.425
3Y1.5952.571-0.976
5Y1.5953.805-2.210
10Y1.5954.462-2.867
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets6,673
Total Liabilities676
Total Stockholder Equity5,997
 As reported
Total Liabilities 676
Total Stockholder Equity+ 5,997
Total Assets = 6,673

Assets

Total Assets6,673
Total Current Assets4,839
Long-term Assets1,834
Total Current Assets
Cash And Cash Equivalents 3,034
Other Current Assets 1,805
Total Current Assets  (as reported)4,839
Total Current Assets  (calculated)4,839
+/-0
Long-term Assets
Intangible Assets 142
Long-term Assets Other 1,692
Long-term Assets  (as reported)1,834
Long-term Assets  (calculated)1,834
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities676
Long-term Liabilities0
Total Stockholder Equity5,997
Total Current Liabilities
Accounts payable 676
Total Current Liabilities  (as reported)676
Total Current Liabilities  (calculated)676
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock18
Retained Earnings -11,499
Other Stockholders Equity 17,478
Total Stockholder Equity (as reported)5,997
Total Stockholder Equity (calculated)5,997
+/-0
Other
Capital Stock18
Cash and Short Term Investments 3,034
Common Stock Shares Outstanding 17,213
Liabilities and Stockholders Equity 6,673
Net Debt -3,034
Net Invested Capital 5,997
Net Working Capital 4,163



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
> Total Assets 
0
0
0
1,036
1,005
978
948
965
972
1,030
5,004
5,768
7,937
6,673
6,6737,9375,7685,0041,0309729659489781,0051,036000
   > Total Current Assets 
0
0
0
437
374
258
116
101
59
38
4,742
4,169
6,050
4,839
4,8396,0504,1694,7423859101116258374437000
       Cash And Cash Equivalents 
0
0
0
437
357
232
99
93
40
21
3,217
1,272
3,616
3,034
3,0343,6161,2723,21721409399232357437000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
1,515
0
0
0
0001,5150000000000
       Other Current Assets 
0
0
0
0
17
26
17
8
19
17
10
38
2,434
1,805
1,8052,4343810171981726170000
   > Long-term Assets 
0
0
0
599
631
720
832
864
913
992
262
1,599
1,887
1,834
1,8341,8871,599262992913864832720631599000
       Intangible Assets 
0
0
0
542
502
462
422
382
342
302
262
222
182
142
142182222262302342382422462502542000
> Total Liabilities 
0
0
0
2,215
2,330
2,539
1,411
3,043
1,891
1,915
1,672
992
805
676
6768059921,6721,9151,8913,0431,4112,5392,3302,215000
   > Total Current Liabilities 
0
0
0
1,633
1,738
1,937
1,411
2,405
1,891
1,915
1,672
992
805
676
6768059921,6721,9151,8912,4051,4111,9371,7381,633000
       Short-term Debt 
0
0
0
4
4
4
0
0
0
0
142
0
0
0
0001420000444000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
142
0
0
0
0001420000000000
       Accounts payable 
0
0
0
1,629
1,734
1,933
1,407
2,401
1,891
1,915
1,530
992
805
676
6768059921,5301,9151,8912,4011,4071,9331,7341,629000
       Other Current Liabilities 
0
0
0
0
0
0
4
0
0
0
0
0
805
0
0805000004000000
   > Long-term Liabilities 
0
0
0
582
592
602
0
638
657
0
0
0
0
0
000006576380602592582000
> Total Stockholder Equity
0
0
0
-1,179
-1,325
-1,561
-463
-2,078
-919
-885
3,332
4,776
7,132
5,997
5,9977,1324,7763,332-885-919-2,078-463-1,561-1,325-1,179000
   Common Stock
0
0
0
10
103
103
11
11
11
11
13
0
500
18
185000131111111110310310000
   Retained Earnings Total Equity00000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
484
0
0484000000000000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
0
0
0
3,211
3,118
3,118
4,620
4,123
5,690
5,892
11,154
0
16,709
17,478
17,47816,709011,1545,8925,6904,1234,6203,1183,1183,211000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-160
Gross Profit-160-160
 
Operating Income (+$)
Gross Profit-160
Operating Expense-2,343
Operating Income-2,343-2,503
 
Operating Expense (+$)
Research Development414
Selling General Administrative1,929
Selling And Marketing Expenses0
Operating Expense2,3432,343
 
Net Interest Income (+$)
Interest Income0
Interest Expense-859
Other Finance Cost-0
Net Interest Income-859
 
Pretax Income (+$)
Operating Income-2,343
Net Interest Income-859
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,603-2,083
EBIT - interestExpense = -3,497
-5,206
-1,744
Interest Expense859
Earnings Before Interest and Taxes (EBIT)-2,638-1,744
Earnings Before Interest and Taxes (EBITDA)-2,343
 
After tax Income (+$)
Income Before Tax-2,603
Tax Provision-0
Net Income From Continuing Ops-2,603-2,603
Net Income-2,603
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,343
Total Other Income/Expenses Net-260859
 

Technical Analysis of Kairos Pharma, Ltd.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kairos Pharma, Ltd.. The general trend of Kairos Pharma, Ltd. is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kairos Pharma, Ltd.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Kairos Pharma, Ltd. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kairos Pharma, Ltd..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.11 < 2.75 < 3.25.

The bearish price targets are: 1.305 > 1.02 > 0.825.

Know someone who trades $KAPA? Share this with them.πŸ‘‡

Kairos Pharma, Ltd. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kairos Pharma, Ltd.. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kairos Pharma, Ltd. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Moving Average Convergence/Divergence (MACD) ChartKairos Pharma, Ltd. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kairos Pharma, Ltd.. The current adx is .

Kairos Pharma, Ltd. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Relative Strength Index (RSI) ChartKairos Pharma, Ltd. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Stochastic Oscillator ChartKairos Pharma, Ltd. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Commodity Channel Index (CCI) ChartKairos Pharma, Ltd. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Chande Momentum Oscillator (CMO) ChartKairos Pharma, Ltd. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Williams %R ChartKairos Pharma, Ltd. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Average True Range (ATR) ChartKairos Pharma, Ltd. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily On-Balance Volume (OBV) ChartKairos Pharma, Ltd. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kairos Pharma, Ltd..

Kairos Pharma, Ltd. Daily Money Flow Index (MFI) ChartKairos Pharma, Ltd. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kairos Pharma, Ltd..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Kairos Pharma, Ltd. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kairos Pharma, Ltd. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.620
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Kairos Pharma, Ltd. with someone you think should read this too:
  • Are you bullish or bearish on Kairos Pharma, Ltd.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kairos Pharma, Ltd.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kairos Pharma, Ltd.

I send you an email if I find something interesting about Kairos Pharma, Ltd..


Comments

How you think about this?

Leave a comment

Stay informed about Kairos Pharma, Ltd..

Receive notifications about Kairos Pharma, Ltd. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.